NewBio Therapeutics (NBT) and University of California, Los Angeles (UCLA) signed a Material Transfer Agreement on February 8, 2016. UCLA’s Translational Oncology Research Laboratory (TORL) will evaluate NBT’s antibody drug conjugates (ADCs) on a series of selected cancer celllines and assess potential collaboration to delvelop ADC therapeutics on mutually agreed novel targets based on NBT’s site-specific conjugation technology and ADC drug development platform